학술논문
Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase
Document Type
Journal
Author
Heudobler, Daniel; Lueke, Florian; Hahn, Joachim; Grube, Matthias; Schlosser, Pavla; Kremers, Stephan; Suedhoff, Thomas; Westermann, Joerg; Huetter-Kroenke, Marie Luise; Schlenk, Richard F.; Weber, Daniela; Paschka, Peter; Zeman, Florian; Doehner, Hartmut; Herr, Wolfgang; Reichle, Albrecht; Thomas, Simone
Source
Subject
Language
English
ISSN
15928721